REGENXBIO Inc. (RGNX) Costs and Expenses USD 2014 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
REGENXBIO Inc. quarterly/annual Costs and Expenses history and growth rate from 2014 to 2024.
  • REGENXBIO Inc. Costs and Expenses for the quarter ending March 31, 2024 was $79.5 M, a 6.81% decline year-over-year.
  • REGENXBIO Inc. Costs and Expenses for the twelve months ending March 31, 2024 was $353 M, a 3.97% decline year-over-year.
  • REGENXBIO Inc. annual Costs and Expenses for 2023 was $358 M, a 4.59% decline from 2022.
  • REGENXBIO Inc. annual Costs and Expenses for 2022 was $376 M, a 21% increase from 2021.
  • REGENXBIO Inc. annual Costs and Expenses for 2021 was $310 M, a 13.4% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $353 M $79.5 M -$5.81 M -6.81% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $358 M $86.1 M -$3 M -3.37% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $361 M $93.9 M -$3.68 M -3.78% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $365 M $93.1 M -$2.1 M -2.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $367 M $85.3 M -$8.45 M -9.01% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $376 M $89.1 M +$4.06 M +4.77% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $372 M $97.6 M +$9.44 M +10.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $362 M $95.2 M +$20.9 M +28.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $341 M $93.7 M +$30.8 M +49% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $310 M $85.1 M +$9.96 M +13.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $300 M $88.1 M +$3.16 M +3.72% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $297 M $74.3 M +$15.9 M +27.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $281 M $62.9 M +$7.58 M +13.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $274 M $75.1 M +$23 M +44.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $251 M $85 M +$34.4 M +67.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $216 M $58.4 M +$13.6 M +30.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $203 M $55.3 M +$18.6 M +50.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $184 M $52.1 M +$13.8 M +35.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 $170 M $50.6 M +$22.6 M +80.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 $148 M $44.8 M +$11.1 M +32.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 $137 M $36.8 M +$6.42 M +21.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 $130 M $38.3 M +$19.7 M +106% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $111 M $28 M +$5.39 M +23.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $105 M $33.7 M +$12.1 M +55.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $93.3 M $30.4 M +$6.99 M +29.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 $86.3 M $18.6 M -$3.53 M -15.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $89.8 M $22.6 M +$3.85 M +20.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 $86 M $21.6 M +$4.29 M +24.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 $81.7 M $23.4 M +$11.7 M +101% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 $69.9 M $22.2 M +$12.2 M +123% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-06
Q3 2016 $57.7 M $18.8 M +$10.3 M +121% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-06
Q2 2016 $47.4 M $17.3 M +$9.67 M +126% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-06
Q1 2016 $37.7 M $11.6 M +$7.01 M +151% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-06
Q4 2015 $30.7 M $9.94 M +$6.58 M +195% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-07
Q3 2015 $24.1 M $8.49 M +$6.3 M +289% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-07
Q2 2015 $17.8 M $7.66 M +$5.51 M +256% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-07
Q1 2015 $12.3 M $4.64 M +$2.54 M +121% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-07
Q4 2014 $9.8 M $3.37 M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-03
Q3 2014 $2.18 M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-03
Q2 2014 $2.15 M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-03
Q1 2014 $2.1 M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.